These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 34469563)

  • 21. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease among children in the United States between 2010 and 2019: An indirect cohort study.
    Andrejko KL; Gierke R; Rowlands JV; Rosen JB; Thomas A; Landis ZQ; Rosales M; Petit S; Schaffner W; Holtzman C; Barnes M; Farley MM; Harrison LH; McGee L; Chochua S; Verani JR; Cohen AL; Pilishvili T; Kobayashi M
    Vaccine; 2024 Jun; 42(16):3555-3563. PubMed ID: 38704263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012.
    Farnham AC; Zimmerman CM; Papadouka V; Konty KJ; Zucker JR; Nattanmai GV; Jose S; Rosen JB
    JAMA Pediatr; 2015 Jul; 169(7):646-52. PubMed ID: 25938798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pneumococcal Conjugate Vaccine Impact on Meningitis and Pneumonia Among Children Aged <5 Years-Zimbabwe, 2010-2016.
    Dondo V; Mujuru H; Nathoo K; Jacha V; Tapfumanei O; Chirisa P; Manangazira P; Macharaga J; de Gouveia L; Mwenda JM; Katsande R; Weldegebriel G; Pondo T; Matanock A; Lessa FC
    Clin Infect Dis; 2019 Sep; 69(Suppl 2):S72-S80. PubMed ID: 31505631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Greece using urinary antigen detection tests: the EGNATIA study, November 2017 - April 2019.
    Liapikou A; Konstantinidis A; Kossyvaki V; Skiadas J; Menegas D; Méndez C; Beavon R; Begier E; Gessner BD; Milionis H; Tsimihodimos V; Baxevanos G; Argiriadou T; Terrovitou C; Toumbis M;
    Hum Vaccin Immunother; 2022 Nov; 18(5):2079923. PubMed ID: 35703733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nasopharyngeal carriage of Streptococcus pneumoniae serotypes among children in India prior to the introduction of pneumococcal conjugate vaccines: a cross-sectional study.
    Sutcliffe CG; Shet A; Varghese R; Veeraraghavan B; Manoharan A; Wahl B; Chandy S; Sternal J; Khan R; Singh RK; Santosham M; Arora NK
    BMC Infect Dis; 2019 Jul; 19(1):605. PubMed ID: 31291902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
    Vanderkooi OG; Scheifele DW; Girgenti D; Halperin SA; Patterson SD; Gruber WC; Emini EA; Scott DA; Kellner JD;
    Pediatr Infect Dis J; 2012 Jan; 31(1):72-7. PubMed ID: 21960186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait.
    Mokaddas E; Albert MJ
    Vaccine; 2012 Dec; 30 Suppl 6():G37-40. PubMed ID: 23228356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial.
    Temple B; Toan NT; Dai VTT; Bright K; Licciardi PV; Marimla RA; Nguyen CD; Uyen DY; Balloch A; Huu TN; Mulholland EK
    Lancet Infect Dis; 2019 May; 19(5):497-509. PubMed ID: 30975525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020.
    Link-Gelles R; Taylor T; Moore MR;
    Vaccine; 2013 May; 31(22):2572-7. PubMed ID: 23583813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Persistent Circulation of Vaccine Serotypes and Serotype Replacement After 5 Years of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine in the United Kingdom.
    Kandasamy R; Voysey M; Collins S; Berbers G; Robinson H; Noel I; Hughes H; Ndimah S; Gould K; Fry N; Sheppard C; Ladhani S; Snape MD; Hinds J; Pollard AJ
    J Infect Dis; 2020 Mar; 221(8):1361-1370. PubMed ID: 31004136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study.
    Ricketson LJ; Bettinger JA; Sadarangani M; Halperin SA; Kellner JD;
    Vaccine; 2022 Apr; 40(19):2733-2740. PubMed ID: 35351324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
    Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
    Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence of invasive pneumococcal disease before and during an era of use of three different pneumococcal conjugate vaccines in Quebec.
    De Wals P; Lefebvre B; Deceuninck G; Longtin J
    Vaccine; 2018 Jan; 36(3):421-426. PubMed ID: 29224962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibiotic resistance and serotype distribution of invasive pneumococcal diseases before and after introduction of pneumococcal conjugate vaccine in the Kingdom of Saudi Arabia (KSA).
    Shibl AM; Memish ZA; Al-Kattan KM
    Vaccine; 2012 Dec; 30 Suppl 6():G32-6. PubMed ID: 23228355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistence of immunity in children aged 2 months and 7 months - 5 years old after primary immunization with 13-valent pneumococcal conjugate vaccine.
    Li G; Ren T; Zhang H; Ti J; Chang X; Yin S; Guan Y; Liu G; Liang Q; Liu J
    Vaccine; 2024 Oct; 42(24):126209. PubMed ID: 39217777
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination.
    Wysocki J; Brzostek J; Szymański H; Tetiurka B; Toporowska-Kowalska E; Wasowska-Królikowska K; Sarkozy DA; Giardina PC; Gruber WC; Emini EA; Scott DA
    Vaccine; 2015 Mar; 33(14):1719-25. PubMed ID: 25698485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pneumococcal Pneumonia Requiring Hospitalization in US Children in the 13-Valent Pneumococcal Conjugate Vaccine Era.
    Olarte L; Barson WJ; Barson RM; Romero JR; Bradley JS; Tan TQ; Givner LB; Hoffman JA; Lin PL; Hultén KG; Mason EO; Kaplan SL
    Clin Infect Dis; 2017 Jun; 64(12):1699-1704. PubMed ID: 28199482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of the introduction of pneumococcal conjugate vaccines on serotype prevalence in Kuwait and Saudi Arabia.
    Mokaddas EM; Shibl AM; Elgouhary A; Elsobky M
    Vaccine; 2018 Oct; 36(43):6442-6448. PubMed ID: 30194003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Invasive pneumococcal pneumonia caused by 13-valent pneumococcal conjugate vaccine types in children with different schedules.
    Lee HY; Hsieh YC; Liu CC; Huang YC; Chang KY; Chi H; Chang LY; Huang YC; Huang LM;
    J Microbiol Immunol Infect; 2018 Apr; 51(2):199-206. PubMed ID: 29021105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.